The U.S. Centers for Medicare & Medicaid Services has assigned a permanent Healthcare Common Procedure Coding System J-code for YARTEMLEA, a drug developed by Omeros Corporation (NASDAQ: OMER). The J-code (J1289) will become effective July 1, 2026.

The permanent code is designed to streamline billing and reimbursement processes for patients covered by U.S. government programs such as Medicare and commercial payers. YARTEMLEA is approved for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and children ages two years and older.

"The assignment of a permanent, product-specific J-code for YARTEMLEA establishes a clear and consistent reimbursement pathway across payors, reducing administrative burden, supporting faster access for patients, and delivering more predictable reimbursement for providers," said Gregory A. Demopulos, Chairman and Chief Executive Officer of Omeros.

YARTEMLEA is the only approved treatment for TA-TMA, a complication of hematopoietic stem cell transplantation. The drug works by inhibiting MASP-2, the effector enzyme of the lectin pathway of complement.

The company stated that together with the existing ICD-10-CM diagnosis code for TA-TMA (M31.11), the new J-code will support standardized coding and billing practices. CMS has published the permanent J-code assignment in its official documentation.

A marketing authorization application for YARTEMLEA is currently under review by the European Medicines Agency, with a decision expected in mid-2026, according to the company's press release statement.